Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer Patients Treated With T-DXd”

23 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 23 results

Not applicableNot Yet RecruitingNCT07465172
What this trial is testing

GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer

Who this might be right for
Breast Cancer
Breast Cancer Trials, Australia and New Zealand 150
Large-scale testing (Phase 3)Not Yet RecruitingNCT07543536
What this trial is testing

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Who this might be right for
Advanced/Metastatic Breast CancerHER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
Sun Yat-sen University 132
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06578286
What this trial is testing

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Who this might be right for
Breast Cancer
Fudan University 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416253
What this trial is testing

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06733233
What this trial is testing

A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

Who this might be right for
Breast Cancer, Estrogen Receptor-PositiveHER2 Low Breast Cancer
Guangzhou Women and Children's Medical Center 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07630103
What this trial is testing

Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 100
Not applicableEnrolling By InvitationNCT07132749
What this trial is testing

NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

Who this might be right for
Patients With HER2-positive Advanced Breast Cancer Treated With T-DXdPatients With HER2-low Advanced Breast Cancer Treated With T-DXd
Yeon Hee Park 100
Post-approval studies (Phase 4)Looking for participantsNCT07195344
What this trial is testing

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.

Who this might be right for
Locally Advanced or Metastatic Breast Cancers
Institut Claudius Regaud 210
Post-approval studies (Phase 4)Not Yet RecruitingNCT07254416
What this trial is testing

A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients

Who this might be right for
Breast Cancer Patients Treated With T-DXd
Tianjin Medical University Cancer Institute and Hospital 120
Testing effectiveness (Phase 2)Looking for participantsNCT07065435
What this trial is testing

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Who this might be right for
HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Not applicableStudy completedNCT05458401
What this trial is testing

EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan

Who this might be right for
HER2-positive Breast Cancer
Daiichi Sankyo 256
Testing effectiveness (Phase 2)Active Not RecruitingNCT06271837
What this trial is testing

T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Who this might be right for
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
AstraZeneca 127
Not applicableStudy completedNCT06833268
What this trial is testing

Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

Who this might be right for
HER2-positive Breast Cancer
Daiichi Sankyo 228
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05953168
What this trial is testing

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Who this might be right for
Triple-Negative Breast Cancer
Fudan University 69
Large-scale testing (Phase 3)Active Not RecruitingNCT04739761
What this trial is testing

T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 506
Testing effectiveness (Phase 2)Looking for participantsNCT07182721
What this trial is testing

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

Who this might be right for
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT04482309
What this trial is testing

T-DXd in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca 477
Not applicableNot Yet RecruitingNCT07035353
What this trial is testing

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Who this might be right for
HER2 OverexpressionAdvanced Stage Breast CancerLow Expression of HER2
Tianjin Medical University Cancer Institute and Hospital 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06797622
What this trial is testing

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast Cancer
Fudan University 50
Not applicableStudy completedNCT06386263
What this trial is testing

HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Who this might be right for
Unresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more
AstraZeneca 22
Load More Results